Z6·尊龙凯时

Be the most trusted biotech company

2023-10-27

Henlius Announces NMPA Approvals of Two ADC Candidates for IND
2023-10-27

Henlius Deepens Collaboration with Intas to bring Henlius’ Novel anti-PD-1 mAb Serplulimab to Europe and India
2023-10-25

First Patient Dosed for MRCT Phase 3 Study on First-Line LS-SCLC of Henlius Anti-PD-1 mAb Serplulimab in Europe
2023-10-24

Results From the Preclinical Study of HLX43, a Potential FIC PD-L1-Targeting ADC Released at 2023 ESMO
2023-10-24

Results From the Preclinical Study of HLX42, a Potential BIC EGFR-Targeting ADC Released at 2023 ESMO
2023-10-20

Henlius Xuhui Facility Passes PIC/S Member ANVISA GMP Inspection for HANLIKANG and HANQUYOU
2023-10-12

Henlius Will be at CPHI Barcelona 2023
2023-10-11

Henlius Xuhui Facility Passes GMP Inspection for HANSIZHUANG by PIC/S Member BPOM
2023-09-22

Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC

1
2
3
4
5
...
8